Pharmacotherapy for Alcohol Use Disorder: Enhancing Health and Treatment Outcomes
DOI:
https://doi.org/10.12775/QS.2025.39.58999Keywords
naltrexone, nalmefene, acamprosate, disulfiram, gabapentin, topiramate, baclofen, N-acetylcysteine, mifepristone, ondansetron, vareniclineAbstract
Introduction and Objective: Alcohol Use Disorder (AUD) combines alcohol abuse and dependence into a single condition characterized by an inability to control alcohol consumption despite its negative consequences. Treatment for AUD includes both pharmacological and behavioral therapies aimed at achieving complete abstinence. This paper reviews pharmacological treatment options and their clinical effectiveness. Given
the increasing prevalence of AUD globally, including in Poland, understanding the availability, efficacy, and cost of these treatments is essential to improve patient outcomes.
Review methods: This review analyzes current literature on pharmacological treatments for AUD, including medications approved by FDA and EMA. Sources include peer-reviewed articles and clinical trials.
Results: Naltrexone and nalmefene have been shown to be effective in reducing alcohol consumption
and cravings, while acamprosate and topiramate are particularly effective in relapse prevention and maintaining abstinence. Gabapentin is effective in treating alcohol withdrawal symptoms, while baclofen, mifepristone,
and N-acetylcysteine show promising results but require further research. Ondansetron has been documented
as effective in treating young patients with early-onset AUD, and varenicline effectively reduces alcohol cravings in individuals with nicotine dependence. The disulfiram implant is ineffective in treating alcohol dependence
and maintaining abstinence, with its action primarily based on the fear of a disulfiram reaction.
Conclusions: Pharmacological treatments for AUD, combined with behavioral therapy, help reduce alcohol consumption or maintain abstinence. Individualized therapy selection is crucial, taking into account the patient's health status and the presence of other conditions. Further research is required to optimize treatment, both in terms of pharmacological mechanisms and better tailoring the therapy to the specific needs of individual patients.
References
1. Mar Y, Whitley SD, Weigand TJ, et al. Treatment of Alcohol Use Disorder [Internet]. Baltimore (MD): Johns Hopkins University; 2023 Oct. PMID: 32845597.
2. Witkiewitz K, Heather N, Falk DE, et al. World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom. Addiction. 2020 Sep;115(9):1668-1680. doi: 10.1111/add.15011. Epub 2020 Mar 10. PMID: 32056311; PMCID: PMC7841874.
3. Burnette EM, Nieto SJ, Grodin EN, et al. Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder. Drugs. 2022 Feb;82(3):251-274. doi: 10.1007/s40265-021-01670-3. Epub 2022 Feb 8. PMID: 35133639; PMCID: PMC8888464.
4. Alcohol Use Disorder: A Comparison Between DSM–IV and DSM–5. https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/alcohol-use-disorder-comparison-between-dsm. [Accessed 10.11.2024].
5. Belnap MA, McManus KR, Grodin EN, et al. Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder. Pharmaceut Med. 2024 Jul;38(4):291-302. doi: 10.1007/s40290-024-00526-x. Epub 2024 Jul 5. PMID: 38967906; PMCID: PMC11272707.
6. Nehring SM, Chen RJ, Freeman AM. Alcohol Use Disorder. 2024 Mar 16. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 28613774.
7. Koob GF. Alcohol Use Disorder Treatment: Problems and Solutions. Annu Rev Pharmacol Toxicol. 2024 Jan 23;64:255-275. doi: 10.1146/annurev-pharmtox-031323-115847. PMID: 38261428.
8. Alcohol Use Disorder (AUD) in the United States: Age Groups and Demographic Characteristics. NIAAA. https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics/alcohol-facts-and-statistics/alcohol-use-disorder-aud-united-states-age-groups-and-demographic-characteristics. [Accessed 02.09.2024].
9. Zimny-Zając A. National Health Test of Poles. REPORT 2022. Ringier Axel Springer Polska. 2022 May. Polish.
10. Pankowski D, Wytrychiewicz-Pankowska K, Kiedik D, et al. Navigating the Shifts: Retrospective Analysis of Alcohol Consumption and its Predictors Across Pre-Pandemic, Lockdown, and Post-Pandemic Eras in Poland. Med Sci Monit. 2023 Nov 7;29:e940768. doi: 10.12659/MSM.940768.
PMID: 37933093; PMCID: PMC10638860.
11. Klimkiewicz A, Klimkiewicz J, Jakubczyk A, et al. Comorbidity of alcohol dependence with other psychiatric disorders. Part I. Epidemiology of dual diagnosis. Psychiatr Pol. 2015 Mar-Apr;49(2):265-75. Polish. doi: 10.12740/PP/25704. PMID: 26093591.
12. Cierniak-Piotrowska M, Dąbrowska A, Potocka M, et al. Population. Size and structure and vital statistics in Poland by territorial division in 2023. As of 31 December. GUS. 2024 Apr. Polish.
13. Bieńkowski P, Wojnar M, Mierzejewski P, et al. Long-term pharmacotherapy aimed at maintaining abstinence or reducing alcohol intake in alcohol-dependent individuals. Guidelines from the Section
of Pharmacotherapy of Polish Society for Research on Addictions (PTBU) and the Section
of Psychopharmacology of Polish Psychiatric Association (PTP) – 2019 update. Pharmacotherapy
in Psychiatry and Neurology. 2019 Oct.
14. Recommendation No. 91/2022 dated September 20, 2022 of the President of the Agency for Health Technology Assessment and Tariff System regarding the assessment of the medicinal product Vivitrol (extended-release naltrexone) for the indication: mental and behavioral disorders caused by alcohol use (F10), including alcohol dependence syndrome. www.aotmit.gov.pl [Accessed 10.12.2024].
15. Karl D, Bumb JM, Bach P, et al. Nalmefene attenuates neural alcohol cue-reactivity in the ventral striatum and subjective alcohol craving in patients with alcohol use disorder. Psychopharmacology (Berl). 2021 Aug;238(8):2179-2189. doi: 10.1007/s00213-021-05842-7. Epub 2021 Apr 12. PMID: 33846866; PMCID: PMC8292278.
16. de Beaurepaire R, Jaury P. Baclofen in the treatment of alcohol use disorder: tailored doses matter. Alcohol Alcohol. 2024 Jan 17;59(2):agad090. doi: 10.1093/alcalc/agad090. PMID: 38266071; PMCID: PMC10807704.
17. Miyata H, Takahashi M, Murai Y, et al. Nalmefene in alcohol-dependent patients with a high drinking risk: Randomized controlled trial. Psychiatry Clin Neurosci. 2019 Nov;73(11):697-706.
doi: 10.1111/pcn.12914. Epub 2019 Aug 5. PMID: 31298784; PMCID: PMC6899457.
18. Mobile application: eMPendium. Polish. [Accessed 06.08.2024]
19. European Commission. ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. https://ec.europa.eu/health/documents/community-register/2016/20161118136085/anx_136085_pl.pdf. [Accessed 05.09. 2024].
20. Nogueira V, Mendes MA, Pereira I, et al. Disulfiram-induced epileptic seizures. BMJ Case Rep. 2021 Mar 17;14(3):e236296. doi: 10.1136/bcr-2020-236296. PMID: 33731397; PMCID: PMC7978088.
21. Wiesner A, Zwierzyńska E, Pietrzak B. The efficacy of topiramate in alcohol dependence therapy – current research and prospects of use. Alcoholism and Drug Addiction/Alkoholizm i Narkomania. 2017;30(3):205-222. doi:10.5114/ain.2017.72314.
22. Falk DE, Ryan ML, Fertig JB, et al. Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety. Alcohol Clin Exp Res. 2019 Jan;43(1):158-169. doi: 10.1111/acer.13917. Epub 2018 Dec 9. PMID: 30403402; PMCID: PMC6317996.
23. Agabio R, Saulle R, Rösner S, et al. Baclofen for alcohol use disorder. Cochrane Database Syst Rev. 2023 Jan 13;1(1):CD012557. doi: 10.1002/14651858.CD012557.pub3. PMID: 36637087; PMCID: PMC9837849.
24. Garbutt JC, Kampov-Polevoy AB, Pedersen C, et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial. Neuropsychopharmacology. 2021 Dec;46(13):2250-2256. doi: 10.1038/s41386-021-01055-w. Epub 2021 Jun 21. PMID: 34155332; PMCID: PMC8580979.
25. Société Française d’Alcoologie. RECOMMANDATION DE BONNE PRATIQUE Mésusage de l’alcool : dépistage, diagnostic et traitement D’après la méthode « Recommandations pour la pratique clinique ». 2023 Jun; https://sfalcoologie.fr/wp-content/uploads/RECOS-SFA-Version-2023-2-2.pdf.
[Accessed 17.11. 2024].
26. Smaga I, Frankowska M, Filip M. N-acetylcysteine as a new prominent approach for treating psychiatric disorders. Br J Pharmacol. 2021 Jul;178(13):2569-2594. doi: 10.1111/bph.15456. Epub 2021 May 5. PMID: 33760228.
27. Calverley P, Rogliani P, Papi A. Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. Drug Saf. 2021 Mar;44(3):273-290. doi: 10.1007/s40264-020-01026-y. Epub 2020 Dec 16. PMID: 33326056; PMCID: PMC7892733.
28. Smilkstein MJ, Knapp GL, Kulig KW, et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med. 1988 Dec 15;319(24):1557-62. doi: 10.1056/NEJM198812153192401. PMID: 3059186.
29. Burnett EJ, Chandler LJ, Trantham-Davidson H. Glutamatergic plasticity and alcohol dependence-induced alterations in reward, affect and cognition. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:309-20. doi: 10.1016/j.pnpbp.2015.08.012. Epub 2015 Sep 1. PMID: 26341050; PMCID: PMC4679411.
30. Lebourgeois S, González-Marín MC, Jeanblanc J, et al. Effect of N-acetylcysteine on motivation, seeking and relapse to ethanol self-administration. Addict Biol. 2018 Mar;23(2):643-652. doi: 10.1111/adb.12521. Epub 2017 May 30. PMID: 28557352.
31. Morais-Silva G, Alves GC, Marin MT. N-acetylcysteine treatment blocks the development of ethanol-induced behavioural sensitization and related ΔFosB alterations. Neuropharmacology. 2016 Nov;110
(Pt A):135-142. doi: 10.1016/j.neuropharm.2016.07.009. Epub 2016 Jul 9. PMID: 27401790.
32. Schneider R Jr, Bandiera S, Souza DG, et al. N-acetylcysteine Prevents Alcohol Related Neuroinflammation in Rats. Neurochem Res. 2017 Aug;42(8):2135-2141. doi: 10.1007/s11064-017-2218-8. Epub 2017 Mar 16. PMID: 28303497.
33. Shen WW. Anticraving therapy for alcohol use disorder: A clinical review. Neuropsychopharmacol Rep. 2018 Sep;38(3):105-116. doi: 10.1002/npr2.12028. PMID: 30175522; PMCID: PMC7292332.
34. Haass-Koffler CL, Magill M, Cannella N, et al. Mifepristone as a pharmacological intervention for stress-induced alcohol craving: A human laboratory study. Addict Biol. 2023 Jul;28(7):e13288.
doi: 10.1111/adb.13288. PMID: 37369125; PMCID: PMC10313137.
35. Simms JA, Haass-Koffler CL, Bito-Onon J, et al. Mifepristone in the central nucleus of the amygdala reduces yohimbine stress-induced reinstatement of ethanol-seeking. Neuropsychopharmacology. 2012 Mar;37(4):906-18. doi: 10.1038/npp.2011.268. Epub 2011 Nov 2. PMID: 22048462; PMCID: PMC3280651.
36. Holtyn AF, Weerts EM. Evaluation of mifepristone effects on alcohol-seeking and self-administration in baboons. Exp Clin Psychopharmacol. 2019 Jun;27(3):227-235. doi: 10.1037/pha0000246. Epub 2018 Dec 20. PMID: 30570274; PMCID: PMC6727199.
37. Vendruscolo LF, Estey D, Goodell V, et al. Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals. J Clin Invest. 2015 Aug 3;125(8):3193-7. doi: 10.1172/JCI79828.
Epub 2015 Jun 29. PMID: 26121746; PMCID: PMC4563748.
38. British Columbia Center on Substance Use (BCCSU). Provincial Guidelines for the Clinical Managment of High-Risk Drinking and Alcohol Use Disorder. 2019;190. Dostępne na stronie: https://www.bccsu.ca/wp-content/uploads/2020/03/AUD-Guideline.pdf
39. Johnson BA. Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. Biochem Pharmacol. 2008;75(1):34-56
40. Johnson BA, Ait-Daoud N, Seneviratne C, et al. Pharmacogenetic Approach at the Serotonin Transporter Gene as a Method of Reducing the Severity of Alcohol Drinking. Am J Psychiat. 2011;168(3):265-275.
41. Johnson BA, Roache JD, Ait-Daoud N, et al. Ondansetron reduces craving in biologically predisposed alcoholics. Psychopharmacology. 2002;160(4):408–413. doi: 10.1007/s00213-002-1002-9. Polish.
42. Freedman SB, Uleryk E, Rumantir M, et al. Ondansetron and the Risk of Cardiac Arrhythmias:
A Systematic Review and Postmarketing Analysis. Ann Emerg Med. 2014;64(1):19-25.
43. Doggrell SA, Hancox JC. Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. Expert Opin Drug Saf. 2013;12(3):421-431.
44. Mitchell JM, Teague CH, Kayser AS, et al. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology (Berl). 2012 Oct;223(3):299-306. doi: 10.1007/s00213-012-2717-x. Epub 2012 May 1. PMID: 22547331; PMCID: PMC3438402.
45. McKee SA, Harrison EL, O'Malley SS, et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry. 2009 Jul 15;66(2):185-90. doi: 10.1016/ j.biopsych.2009.01.029. Epub 2009 Feb 27. PMID: 19249750; PMCID: PMC2863311.
46. Fucito LM, Toll BA, Wu R, et al. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berl). 2011 Jun;215(4):655-63. doi: 10.1007/ s00213-010-2160-9. Epub 2011 Jan 11. PMID: 21221531; PMCID: PMC3645986.
47. Phimarn W, Sakhancord R, Paitoon P, et al. Efficacy of Varenicline in the Treatment of Alcohol Dependence: An Updated Meta-Analysis and Meta-Regression. Int J Environ Res Public Health. 2023 Feb 24;20(5):4091. doi: 10.3390/ ijerph20054091. PMID: 36901103; PMCID: PMC10001935.
48. Haeny AM, Gueorguieva R, Montgomery L, et al. The eect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials. Addict Behav. 2021 Nov;122:106970.
doi: 10.1016/j.addbeh.2021.106970. Epub 2021 May 1. PMID: 34216871; PMCID: PMC9426655.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Katarzyna Moczyróg, Aleksandra Sierpińska, Agata Jaksz, Maria Jasiewicz, Patrycja Karnas-Bogacka, Marta Malicka, Aleksandra Kozioł, Piotr Mól
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 35
Number of citations: 0
